U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H13N5O5S2
Molecular Weight 383.403
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFTIZOXIME

SMILES

[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C3=CSC(N)=N3)C(O)=O

InChI

InChIKey=NNULBSISHYWZJU-LLKWHZGFSA-N
InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1

HIDE SMILES / InChI

Description

Ceftizoxime is a semisynthetic cephalosporin antibiotic, which can be administered intravenously or intramuscularly. It was sold under brand name, cefizox, but was removed from the US Market in 2007. Cefizox was used to treat different infections, such as lower respiratory tract infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenza; urinary tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. Also for treatment of gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae; pelvic inflammatory disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae; meningitis caused by Haemophilus influenza. In addition, some others infections. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae. Infections caused by aerobic gram ¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. The bactericidal action of ceftizoxime results from inhibition of the third and last stage of bacterial cell wall synthesis. Bacterial cell wall autolytic enzymes such as autolysins then mediate cell lysis; it is possible that ceftizoxime interferes with an autolysin inhibitor. Ceftizoxime is highly resistant to a broad spectrum of beta -lactamases (penicillinase and cephalosporinase), including Richmond types II, III, TEM, IV, produced by both aerobic and anaerobic gram - positive and gram - negative organisms and I.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: Ceftizoxime was undetectable or its concentration very low in the cerebrospinal fluid (CSF), when there was no inflammation in the meninges.

Originator

Approval Year

1983
81
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
CEFIZOX

Approved Use

Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenzae including ampicillin-resistant strains; Staphylococcus aureus (penicillinase¬ and nonpenicillinase-producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae, but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. including P.aeruginosa; Proteus mirabilis; P. vulgaris; Providencia rettgeri (formerly Proteus rettgeri) and Morganella morganii (formerly Proteus morganii); Klebsiella spp.; Serratia spp. including S. marcescens; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae. Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae. NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti¬chlamydial coverage should be added. Intra¬Abdominal Infections caused by Escherichia coli; Staphylococcusepidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Bacteroides spp. including B. fragilis; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Staphylococcus epidermidis; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Streptococcus spp. (excluding enterococci); Proteusmirabilis; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae. Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings.

Launch Date

4.32431989E11
Curative
Approved
8429
CEFIZOX

Approved Use

Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenzae including ampicillin-resistant strains; Staphylococcus aureus (penicillinase¬ and nonpenicillinase-producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae, but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. including P.aeruginosa; Proteus mirabilis; P. vulgaris; Providencia rettgeri (formerly Proteus rettgeri) and Morganella morganii (formerly Proteus morganii); Klebsiella spp.; Serratia spp. including S. marcescens; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae. Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae. NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti¬chlamydial coverage should be added. Intra¬Abdominal Infections caused by Escherichia coli; Staphylococcusepidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Bacteroides spp. including B. fragilis; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Staphylococcus epidermidis; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Streptococcus spp. (excluding enterococci); Proteusmirabilis; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae. Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings.

Launch Date

4.32431989E11
Curative
Approved
8429
CEFIZOX

Approved Use

Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenzae including ampicillin-resistant strains; Staphylococcus aureus (penicillinase¬ and nonpenicillinase-producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae, but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. including P.aeruginosa; Proteus mirabilis; P. vulgaris; Providencia rettgeri (formerly Proteus rettgeri) and Morganella morganii (formerly Proteus morganii); Klebsiella spp.; Serratia spp. including S. marcescens; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae. Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae. NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti¬chlamydial coverage should be added. Intra¬Abdominal Infections caused by Escherichia coli; Staphylococcusepidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Bacteroides spp. including B. fragilis; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Staphylococcus epidermidis; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Streptococcus spp. (excluding enterococci); Proteusmirabilis; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae. Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings.

Launch Date

4.32431989E11
Curative
Approved
8429
CEFIZOX

Approved Use

Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenzae including ampicillin-resistant strains; Staphylococcus aureus (penicillinase¬ and nonpenicillinase-producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae, but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. including P.aeruginosa; Proteus mirabilis; P. vulgaris; Providencia rettgeri (formerly Proteus rettgeri) and Morganella morganii (formerly Proteus morganii); Klebsiella spp.; Serratia spp. including S. marcescens; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae. Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae. NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti¬chlamydial coverage should be added. Intra¬Abdominal Infections caused by Escherichia coli; Staphylococcusepidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Bacteroides spp. including B. fragilis; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Staphylococcus epidermidis; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Streptococcus spp. (excluding enterococci); Proteusmirabilis; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae. Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings.

Launch Date

4.32431989E11
Curative
Approved
8429
CEFIZOX

Approved Use

Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenzae including ampicillin-resistant strains; Staphylococcus aureus (penicillinase¬ and nonpenicillinase-producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae, but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. including P.aeruginosa; Proteus mirabilis; P. vulgaris; Providencia rettgeri (formerly Proteus rettgeri) and Morganella morganii (formerly Proteus morganii); Klebsiella spp.; Serratia spp. including S. marcescens; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae. Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae. NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti¬chlamydial coverage should be added. Intra¬Abdominal Infections caused by Escherichia coli; Staphylococcusepidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Bacteroides spp. including B. fragilis; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Staphylococcus epidermidis; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Streptococcus spp. (excluding enterococci); Proteusmirabilis; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae. Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings.

Launch Date

4.32431989E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
34721 μg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26896348
0.5 g single, intravenous
dose: 0.5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFTIZOXIME serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
51 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6296034
0.5 g single, intravenous
dose: 0.5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFTIZOXIME serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
68631 μg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26896348
0.5 g single, intravenous
dose: 0.5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFTIZOXIME serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6296034
0.5 g single, intravenous
dose: 0.5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFTIZOXIME serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.57 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26896348
0.5 g single, intravenous
dose: 0.5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFTIZOXIME serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg/kg 1 times / day steady, intravenous
Studied dose
Dose: 100 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 100 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6296023
unhealthy, 1 month-18 years
n = 1
Health Status: unhealthy
Age Group: 1 month-18 years
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6296023
Sources:
https://pubmed.ncbi.nlm.nih.gov/6296023
500 mg single, intramuscular
Studied dose
Dose: 500 mg
Route: intramuscular
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6272631
healthy, 25- 43 years
Health Status: healthy
Age Group: 25- 43 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/6272631
Sources:
https://pubmed.ncbi.nlm.nih.gov/6272631
2 g 2 times / day steady, intravenous
Studied dose
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6321356
unhealthy
Health Status: unhealthy
Condition: complicated urinary tract infections
Sources:
https://pubmed.ncbi.nlm.nih.gov/6321356
Sources:
https://pubmed.ncbi.nlm.nih.gov/6321356
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OAT1
599

OAT3
642
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OAT1
603
 yes [IC50 3598.6 uM]
OAT3
644
 yes [IC50 956.7 uM]
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:553473
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:553473
ChemicalBook
CB1717299
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1717299
MolPort
MolPort-006-167-775
https://www.molport.com/shop/molecule-link/MolPort-006-167-775
ZINC
ZINC000003830477
http://zinc15.docking.org/substances/ZINC000003830477
PubMed

PubMed

TitleDatePubMed
Susceptibility of intra- and extracellular Mycobacterium avium-intracellulare to cephem antibiotics.
1985 Jan
Determination of in vitro susceptibility of Mycobacterium tuberculosis to cephalosporins by radiometric and conventional methods.
1985 Jan
[A comparative, well-controlled study of ceftizoxime suppository against ceftizoxime intravenous injection in infantile acute pneumonia].
1986 May
Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome.
1987 Oct
Comparison of in vitro antimicrobial susceptibilities of Mycobacterium avium-M. intracellulare strains from patients with acquired immunodeficiency syndrome (AIDS), patients without AIDS, and animal sources.
1990 Jul
Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1.
2005 Oct 1
A case of immune hemolytic anemia induced by ceftizoxime and cefobactam (sulbactam/cefoperazone).
2009 Dec
Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity.
2015 Mar
Patents

Patents

JP2001500477A
122
JP2002541113A
46
JP2002542249A
12
JP2003515526A
462
JP2008017723A
9
JP2009541210A
79
JP2011528275A
455
JP4763957B2
87
JP4849764B2
75
JPH02157225A
4
JPH02212494A
4
JPH02250829A
4
JPH05227992A
4
JPH1180164A
4
JPS57158719A
4
JPS5726692A
4

Sample Use Guides

In Vivo Use Guide
The usual adult dosage is 1 or 2 grams of Cefizox (ceftizoxime for injection, USP) every 8 to 12 hours. Proper dosage and route of administration should be determined by the condition of the patient, severity of the infection, and susceptibility of the causative organisms. Uncomplicated Urinary Tract - 1 grams; 500 mg q12h IM or IV Severe or Refractory - 3-6 grams; 1 gram q8h IM or IV; 2 grams q8-12h IM or IV Because of the serious nature of urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. A single, 1 gram IM dose is the usual dose for treatment of uncomplicated gonorrhea. The IV route may be preferable for patients with bacterial septicemia, localized parenchymal abscesses (such as intra¬abdominal abscess), peritonitis, or other severe or life¬threatening infections. In those with normal renal function, the IV dosage for such infections is 2 to 12 grams of Cefizox (ceftizoxime for injection, USP) daily. In conditions such as bacterial septicemia, 6 to 12 grams/day may be given initially by the IV route for several days, and the dosage may then be gradually reduced according to clinical response and laboratory findings.
Route of Administration: Other
In Vitro Use Guide
The in vitro activity of ceftizoxime was tested by determining minimal inhibitory concentrations (MIC) by agar dilution method, for 150 strains of genus Pasteurella and group EF4 bacteria from various sources. All the strains were susceptible to ceftizoxime and inhibited by 0.03 micrograms/ml concentration. No significant difference appeared between the 7 species and human and animal strains. Group EF4 bacteria, frequently isolated from animal bite wounds in humans, had higher MIC (O.25-1 micrograms/ml).
Name Type Language
CEFTIZOXIME
INN   MI   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
CEFTIZOXIME [JAN]
Common Name English
Ceftizoxime [WHO-DD]
Common Name English
ceftizoxime [INN]
Common Name English
CEFTIZOXIME [USP-RS]
Common Name English
(6R,7R)-7-(((2Z)-2-(2-AMINO-1,3-THIAZOL-4-YL)-2-METHOXYIMINOACETYL)AMINO)-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
CEFTIZOXIME [MI]
Common Name English
CEFTIZOXIME [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
LIVERTOX NBK547862
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
LIVERTOX NBK548666
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NCI_THESAURUS C357
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
WHO-VATC QJ01DD07
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
WHO-ATC J01DD07
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000175488
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
Code System Code Type Description
DRUG CENTRAL
563
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
INN
4743
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
SMS_ID
100000082061
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
DAILYMED
C43C467DPE
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
ChEMBL
CHEMBL528
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
CAS
68401-81-0
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
RXCUI
2192
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY RxNorm
WIKIPEDIA
Ceftizoxime
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
MERCK INDEX
m3222
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY Merck Index
PUBCHEM
6533629
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
RS_ITEM_NUM
1098173
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
NCI_THESAURUS
C61668
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
LACTMED
Ceftizoxime
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID5022772
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
DRUG BANK
DB01332
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
FDA UNII
C43C467DPE
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
CHEBI
553473
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
EVMPD
SUB07429MIG
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
MESH
D015296
Created by admin on Fri Dec 15 15:23:54 UTC 2023 , Edited by admin on Fri Dec 15 15:23:54 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of CEFTIZOXIME
PRODRUG (METABOLITE ACTIVE)
Structure of CEFTIZOXIME ALAPIVOXIL
SALT/SOLVATE (PARENT)
Structure of CEFTIZOXIME SODIUM
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966